Efficacy and safety of acarbose in metformin-treated patients with type 2 diabetes. Diabetes Care 1998;21:2050–2055. 44. Fonseca V, Rosenstock J, Patwardhan R, Salzman A: Effect of metformin and rosiglitazone combinationtherapy in patients with type 2 diabetes mellitus: A randomized controlled trial. JAMA 2000;283:1695–1702. 45. American Diabetes Association: Standards of medical care for patients with diabetes mellitus (position state-ment). Diabetes Care 2002;25(Suppl):S33–S49. 46. Buse JB, Henry R, Han J, Kim DD, Fineman MS, Baron AD: Effect of exenatide (exendin-4) on glycemic con-trol and safety over 30 weeks in sulfonylurea-treatedpatients with type 2 diabetes. Diabetes Care 2004;53:A82. 47. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD: Effects of exenatide (exendin-4) onglycemic control and weight over 30 weeks in met-formin-treated patients with type 2 diabetes. Diabetes Care 2005;28:1092–1100.48. Kendall DM, Riddle MC, Rosenstock J, Zhuang D,